Table 2.
Articles describing the infection eradication rate using antibiotic-loaded spacers
| First Author, year, (country) | N° of joints (N patients) | Joint | Type of spacer (N) | Antibiotic, total dose (amounta) | Rate (%) of reimplantation | Infection eradication rate (%) |
|---|---|---|---|---|---|---|
| Radoicic et al. 2016 [56] (Serbia) | 18 | Knee | Handmade | VAN 2 g (high) | 67 | 89 |
| ERT 4 g (high) | ||||||
| CZA 2–4 g (high) | ||||||
| Dias Carvalho et al. 2021 [62] (Portugal) | 58 | Hip and Knee | Commercial G (14) | GEN (low) | 100 | 57b |
| Commercial G-V (24) | GEN + VAN (high) | |||||
| Handmade (20) | VAN 3 g + MER 2 g + GEN 0.5 g (high) | 89b,c | ||||
| Ortola et al. 2017 [57] (Italy) | 112 | Knee | Handmade | CLI 1 g + GEN 1 g (high) | 75 | 96 |
| CLI 1 g + GEN 1 g + VAN 4 g (high) | 92 | 98 | ||||
| Vasarhelyi et al. 2022 [58] (Canada) | 176 | Knee | Handmade | VAN 2 g and TOB or GEN 2.4 g (high) | NA | 87 |
| Corona et al. 2013 [59] (Spain) | 46 (41) | Hip and Knee | Commercial G (20) | GEN 0.8 g to 3.2 g (low) | 100 | 80 |
| Commercial G + V (26) | VAN + GEN (1:1) 0.8g to 3.2g (high) | 88 | 85 | |||
| Uchiyama et al. 2013 [60] (Japan) | 37 (36) | Hip | Handmade | GEN 1.2 g (low) | 86 | 81 |
| GEN + VAN 2 g if MRSA (high) | 60 | |||||
| Nodzo et al. 2017 [61] (USA) | 140 | Knee | Commercial (58) | VAN 1 g + AG 3.8 g (high)d | 140 (100%) | 83 |
| Molds (43) | VAN 2.7 g + AG 4.4 g (high)d | 88 | ||||
| Tibial mold femoral autoclaved (39) | VAN 2 g + AG 2 g (high)d | 79 |
VAN Vancomycin, ERT Ertapenem, CZA Ceftazidime, GEN Gentamicin, CLI Clindamycin, MER Meropenem, TOB Tobramycin, AG Aminoglycoside
aFor definition see the text
bEradication evaluated as culture negative at second stage
cEradication rate of both groups GEN+VAN or VAN+MER+GEN
dMedian dose of each antibiotic